TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03178084
Drug: Efavirenz QD + Zidovudine/Lamivudine BID
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: efavirenz (600 mg once daily) added to zidovudine/lamivudine (300 mg/150 mg twice daily)
Study: NCT03178084
Drug: Maraviroc (UK-427,857) BID + Zidovudine/Lamivudine QD
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: maraviroc (UK-427,857) 300 mg twice daily added to zidovudine/lamivudine (300 mg/150 mg twice daily
Study: NCT03816761
Drug: Fast-acting insulin aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In each cohort, participants will receive fast-acting insulin aspart using the iLet™ in a cross-over manner for 14 days (7days per period). Dose modification will be handled autonomously by the iLet™ based on the CGM sensor readings and the user interaction with the iLet™ e.g. meal announcements.
Study: NCT01030393
Drug: human chorionic gonadotrophin
Normalized name: Human chorionic gonadotrophin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intrauterine injection of 100 iu (group1) or 200 iu (group2) of hCG before embryo transfer in IVF/ICSI And intrauterine injection of 500 iu hCG before embryo transfer .
Study: NCT02671760
Drug: SM-1
Normalized name: SM-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-drug combination product containing 50 mg diphenhydramine, 5 mg zolpidem and 0.5 mg lorazepam
Study: NCT01682551
Drug: Chinese Medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
DrugBank: Butylene glycol (DB14110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participators in this arm will take 2g (powder in capsule) of Wu Zhu Yu Tang or placebo orally three times in the first day and one time in the second day.
Study: NCT01682551
Drug: Acetalozamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If the participators have the history of AMS, he/she will be randomized to take Wu Zhu Yu Tang plus placebo of Acetalozamide or Acetalozamide plus placebo of Wu Zhu Yu Tang.
Study: NCT03349619
Drug: Resveratrol plus Carboxymethyl-β-Glucan
Normalized name: sodium carboxymethyl beta-glucan (DS 0.65-0.85)
DrugBank: Resveratrol (DB02709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this arm will receive Resveratrol plus Carboxymethyl-β-Glucan, two sprays (100µL/spray) per nostril three times/day for 4 weeks
Study: NCT01820520
Drug: brilliant blue G
Normalized name: Brilliant blue G
DrugBank: Brilliant blue G (DB15594)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Double staining with brilliant blue G 0.025% for macular surgery
Study: NCT00821262
Drug: sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00821262
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00159263
Drug: Formoterol Inhalant Powder
Normalized name: formoterol Inhalation Powder
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 12ug
Study: NCT00159263
Drug: Budesonide Powder
Normalized name: budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Inhaler
Study: NCT00159263
Drug: Budesonide and Formoterol Product
Normalized name: formoterol and budesonide
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Combination Inhaler, Symbicort
Study: NCT02841267
Drug: PF 06252616
Normalized name: PF-06252616
DrugBank: Domagrozumab (DB15083)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03003546
Drug: Nab-paclitaxel/Rituximab-coated Nanoparticle AR160
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00183443
Drug: Divalproex-extended release (DVP-ER)
Normalized name: divalproex sodium Extended Release Oral Tablet
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divalproex ER will be given in 250 mg or 500 mg tablets. Dosing is once a day, every day, for the duration of study participation, either 12 or 26 weeks.
Study: NCT00183443
Drug: Lithium
Normalized name: Lithium
DrugBank: Lithium citrate (DB14507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended release lithium will be provided in 300 mg capsules. Participants will be dosed to a therapeutic blood level of lithium from 0.8 to 1.2 mcg/L.
Study: NCT00183443
Drug: Quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine will be dosed to efficacy, provided in 50 mg, 100 mg, 200 mg, or 300 mg pills.
Study: NCT01484431
Drug: Tadalafil- Tablet or Oral suspension
Normalized name: tadalafil Oral Tablet
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadalafil Tablets administered orally. Tadalafil Oral suspension: An aqueous, ready-to-use suspension for oral administration.
Study: NCT00088933
Drug: recombinant vaccinia-CEA(6D)-TRICOM vaccine
Normalized name: Smallpox (Vaccinia) Vaccine, Live
DrugBank: Smallpox (Vaccinia) Vaccine, Live (DB14711)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given intradermally
Study: NCT00088933
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00088933
Drug: sargramostim
Normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given subcutaneously
Study: NCT03085836
Drug: TAK-438
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-438 tablets.
Study: NCT01079351
Drug: Intravenous Carbamazepine
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg/mL of intravenous Carbamazepine (CBZ) dissolved in 250 mg/mL of Captisol® (cyclodextrin) dosed at 70% of the patient's daily maintenance dose of oral CBZ administered after suitable dilution with D5W by intravenous infusion every 6 hours.
Study: NCT05364567
Drug: cholecalciferol (vitamin D3)
Normalized name: cholecalciferol (vitamin D3)
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study group with vitamin D deficiency was treated with intramuscular injection of 200,000 IU cholecalciferol (Kwangdong Pharmaceutical Co., Seoul, Korea) once at baseline.
Study: NCT00918879
Drug: Saxagliptin
Normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablet, once daily for 24 weeks
Study: NCT01205022
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01431820
Drug: Luliconazole Solution, 10%
DrugBank: Luliconazole (DB08933)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical
Study: NCT02999191
Drug: BI 1467335 (Treatment A)
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02999191
Drug: BI 1467335 (Treatment B)
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02999191
Drug: BI 1467335 (Treatment C)
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00777738
Drug: BORTEZOMIB
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * Bortezomib (Velcade(R)): 1.3 mg/m2 on Days 1, 4, 8, and 11 every 21 days for 2 cycles (IV route, push).~* For responding patients : up to 6 cycles~* For non responding patient : Adjunction of dexamethasone (HD DXM) : 20 mg Days 1,D2, D 4,D 5, D8, D9 and D 11,D12 every 21 days
Study: NCT00685139
Drug: Zonisamide 100 mg Capsule
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 mg capsule administered after an overnight fast.
Study: NCT00685139
Drug: Zonisamide (Zonegran®) 100 mg Capsule
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 mg capsule administered after an overnight fast.
Study: NCT00138229
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00565812
Drug: SD-6010
Normalized name: Alphanine SD
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg tablets once a day for 2 years
Study: NCT00565812
Drug: SD-6010
Normalized name: Alphanine SD
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg tablets once a day for 2 years
Study: NCT01909219
Drug: Sodium picosulphate/magnesium Citrate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Comparison of two different dosing regimens of sodium picosulphate/magnesium citrate
Study: NCT02329600
Drug: green tea tablets (Green tea extract 5:1) 200 mg
Normalized name: Green Tea Extract
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea is a product made from the Camellia sinensis plant. The fresh leaves are used to make medicine. the green tea extract is presented in a form of tablets 200 mg and is taken orally.
Study: NCT02329600
Drug: Triamcinolone Acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: topical corticosteroids (Kenalog in orabase: Bristol-Myers, Squibb, Spain) applied topically 4 times a day i.e. following each meal and at bed time for one month
Study: NCT00865111
Drug: Bupropion 150 mg Extended-Released Tablet, single dose
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A: Experimental Subjects received Abrika formulated products under fasting conditions
Study: NCT04374500
Drug: Leptin infusion plus vasodilators in healthy men
Normalized name: leptin
DrugBank: Leptin (DB05098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This applies only to protocol 2 with two arms (leptin or saline) where four vasodilatators (bradykinin, acetylcholine, sodium nitroprusside and verapamil) were infused concomitantly
Study: NCT04374500
Drug: Leptin infusion in healthy men
Normalized name: leptin
DrugBank: Leptin (DB05098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This applies only to protocol 1 when only leptin was given
Study: NCT04505995
Drug: Azacitidine and homoharringtonine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Concommitant use of azacitidine and homoharringtonine
Study: NCT01352702
Drug: Dabigatran
Normalized name: Dabigatran
DrugBank: Dabigatran (DB14726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients assigned to this group will receive Dabigatran
Study: NCT01352702
Drug: Phenprocoumon
Normalized name: phenprocoumon
DrugBank: Phenprocoumon (DB00946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients assigned to this group will receive Phenprocoumon
Study: NCT00689169
Drug: ZBEAM (Zevalin, BCNU, Etoposide, Aracytine, Melphalan)
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zevalin 0.4 mCi/kg: D-14 BCNU 300 mg/m² : D-6 Etoposide 100 mg/m²/12h : D-6 D-5 D-4 D-3 Aracytine 200 mg/m²/12h : D-6 D-5 D-4 D-3 Melphalan 140 mg/m²: D-2
Study: NCT00689169
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 250 mg/m² :D-21 D-14
Study: NCT03854812
Drug: Magnesium Sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: a loading of 50 mg/kg in 15 minutes of Magnesium sulphate, and will be followed by continuous infusion at 1 ml/kg/h of 15 mg/ml solution
Study: NCT00666900
Drug: High Strength IDP-107
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a day for 12 weeks
Study: NCT00402012
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During the double-blind, 12 weeks treatment period, subjects will self-administer study medication (pioglitazone or equivalent volume of placebo) 30 mg/day each morning. The dose of pioglitazone will be increased to 45 mg/day after 4 weeks if the fasting plasma glucose is higher than 100mg/dl or the HbA1C is higher than 7%. This dose has proven tolerability, safety and efficacy for type 2 diabetes and has previously been used at the Pennington Center in studies on pioglitazone.
Study: NCT03854812
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5-1.5 mg/kg bolus of propofol over 10 minutes to achieve target Ramsay sedation scale (RSS) of 3 (respond to command), if RSS afterwards does not reach 3 a supplementary bolus dose of 0.2 mg/kg propofol will be given to the patients, and will be followed by 1-2.5 mg/kg/hr infusion to maintain Intraoperative BIS readings between 60 - 80
Study: NCT02079519
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab was provided as a concentrate in vials.
Study: NCT02056626
Drug: carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01549704
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm RP is receiving 30 ml of ropivacaine 7,5 mg/ml at first blockade (ACB) and after 45 minutes another blockade (ACB) with placebo (saline 30 ml).~Arm PR is receiving 30 ml of placebo (saline) at first blockade (ACB) and after 45 minutes another blockade (ACB)with ropivacaine.
Study: NCT01549704
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: please see intervention description for ropivacaine
Study: NCT03691077
Drug: Ocrelizumab
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The first dose of ocrelizumab will be administered as two 300-mg IV infusions (600 mg total) in 250 mL 0.9% sodium chloride each separated by 14 days (i.e., Days 1 and 15), followed by one 600-mg IV infusion in 500 mL 0.9% sodium chloride every subsequent doses (i.e., every 24 weeks) for 72 weeks.
Study: NCT01532804
Drug: bevacizumab, oxaliplatin and 5FU combination
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 5 mg/kg administered as an iv infusion for 1h30, then for 1h and for 30 min. at the following cycles, respectively.~Oxaliplatin 85 mg/m² administered as an iv infusion for 2h Elvorine 200 mg/m² administered as an iv infusion for 2h 5FU 400 mg/m2 bolus then 5FU 2,400 mg/m² iv infusion for 46h D1=D15 (12 cycles)
Study: NCT01532804
Drug: Bevacizumab, oxaliplatin and raltitrexed combination
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 7.5 mg/kg administered as an iv infusion for 1h30, then administered for 1h and 30 min at the following cycles, respectively.~Oxaliplatin 130 mg/m² administered as an iv infusion for 2h Raltitrexed 3 mg/m² administered as an iv infusion for 15 min
Study: NCT00234702
Drug: Lanthanum carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lanthanum carbonate 750mg/day, T.I.D. for 2 weeks; titrated at the next 3 weekly visits in order to achieve target serum phosphorus levels, up to a maximum dose of 3000mg/day; 4-week maintenance period where subject receives the final titrated daily dose established during the titration period.
Study: NCT02775370
Drug: Apatinib Mesylate
Normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib Mesylate will be administered orally at 500 mg once daily for 5 consecutive days, and this was followed by a 2-day rest every week; each cycle consisted of 28 days
Study: NCT01365936
Drug: rFSH
Normalized name: rFSH-alpha
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients were randomized after GnRH analogue suppression to stimulation with HMG (n=38) or rFSH (n=42) using a low dose step up protocol in ICSI cycles.
Study: NCT00266123
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04447105
Drug: total intravenous anesthesia with propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the TIVA group, general anesthesia is induced and maintained with a target-controlled infusion of propofol using infusion pump (Orchestra®; Fresenius Vial, Brezins, France). In both groups, remifentanil is continuously infused throughout the surgery for balanced anesthesia, adjusted to maintain arterial pressure.
Study: NCT04447105
Drug: inhalation anesthesia with desflurane
Normalized name: desflurane Inhalation Solution
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the desflurane group, anesthesia is induced with propofol 1-2 mg/kg and maintained with desflurane (5-7 vol %). In both groups, remifentanil is continuously infused throughout the surgery for balanced anesthesia, adjusted to maintain arterial pressure.
Study: NCT02037477
Drug: Vonoprazan
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Vonoprazan tablets
Study: NCT02037477
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole capsules
Study: NCT02037477
Drug: Rabeprazole sodium
Normalized name: Rabeprazole Sodium
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rabeprazole sodium tablets
Study: NCT00218231
Drug: 300 mg/day bupropion-sr
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg/day for 1 week
Study: NCT00218231
Drug: 0 mg/day bupropion-sr
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0 mg/day bupropion-sr
Study: NCT03867695
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At the end of the lobectomy VATS procedure, 0,5 mL/kg of 0.375% ropivacaine will be administered.
Study: NCT01134224
Drug: insulin degludec/insulin aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.4 U/kg body weight injected subcutaneously (under the skin) once
Study: NCT01134224
Drug: insulin degludec/insulin aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.6 U/kg body weight injected subcutaneously (under the skin) once
Study: NCT01134224
Drug: insulin degludec/insulin aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.8 U/kg body weight injected subcutaneously (under the skin) once
Study: NCT01134224
Drug: biphasic insulin aspart 30
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.4 U/kg body weight injected subcutaneously (under the skin) once
Study: NCT01134224
Drug: biphasic insulin aspart 30
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.6 U/kg body weight injected subcutaneously (under the skin) once
Study: NCT01134224
Drug: biphasic insulin aspart 30
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.8 U/kg body weight injected subcutaneously (under the skin) once
Study: NCT00876824
Drug: Amphotericin B Lipid emulsion
Normalized name: AMPHOTERICIN B LIPID COMPLEX
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B lipid emulsion (Amphomul) 15 mg/kg on day 1 in group A for treatment of Visceral Leishmaniasis
Study: NCT00876824
Drug: Liposomal Amphotericin B
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal Amphotericin B in visceral leishmaniasis - 15 mg/kg on day 1 in group B
Study: NCT01182441
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin dosage prescribed by study physician to adequately maintain an INR of 2.0-3.0
Study: NCT00603525
Drug: Ofatumumab
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each treatment cycle consisting of two IV infusion taken 14 days apart. A total of 8 infusion cycles given over a 144 week period
Study: NCT00284908
Drug: S-Tenatoprazole-Na (STU-Na)
Normalized name: sulfacetamide sodium Ophthalmic Solution [S.O.S.S.]
DrugBank: Sulfacetamide (DB00634)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg, 60 mg, 90 mg and 120 mg of STU-Na for 5 days every morning
Study: NCT01049451
Drug: ACTH
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects assigned to the ACTH arm will receive ACTH (Acthar gel) as intramuscular (IM) injections once a day for 3 consecutive days on a monthly basis, for 12 consecutive months. The dosage of ACTH will be 80 units per injection, for a total of 240 units over the three day period.
Study: NCT03990363
Drug: Verinurad
Normalized name: Verinurad
DrugBank: Verinurad (DB11873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study treatments will be titrated in 3 steps for target low dose (3 mg), intermediate dose ( 7.5 mg) and High Dose (12 mg) Verinurad.~As per Protocol Version 5.0, Patients from 3 mg dose will be switched to 24 mg at visit 9
Study: NCT03990363
Drug: Allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study treatments will be titrated in 3 steps: Low dose (100 mg), intermediate (200 mg) and High Dose ( 300 mg) Allopurinol
Study: NCT03990363
Drug: Placebo for Verinurad
DrugBank: Verinurad (DB11873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Capsule
Study: NCT03990363
Drug: Placebo for Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Matching tablet
Study: NCT01049451
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects assigned to the MP arm will receive intravenous (IV) infusions of 1 gram of MP once a month for 12 months
Study: NCT02784457
Drug: Cetrorelix
Normalized name: Cetrorelix
DrugBank: Cetrorelix (DB00050)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00218114
Drug: Divalproex Sodium
Normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants are titrated over 2 weeks, as tolerated to 10 mgs / pound, and blood levels are checked to determine that the blood level is between 50-110 micrograms / ml.
Study: NCT00350597
Drug: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
Normalized name: Recombinant human granulocyte-macrophage colony stimulating factor
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no